Q1 EPS Estimates for Zimmer Biomet Reduced by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities researchers at Zacks Research decreased their Q1 2025 earnings per share estimates for shares of Zimmer Biomet in a research note issued to investors on Thursday, February 27th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $1.80 per share for the quarter, down from their previous estimate of $2.01. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q2 2025 earnings at $2.07 EPS, Q3 2025 earnings at $1.96 EPS, Q4 2025 earnings at $2.52 EPS, FY2025 earnings at $8.35 EPS, Q1 2026 earnings at $2.11 EPS, Q2 2026 earnings at $2.25 EPS, Q3 2026 earnings at $2.17 EPS, Q4 2026 earnings at $2.31 EPS, FY2026 earnings at $8.84 EPS and FY2027 earnings at $9.37 EPS.

Several other equities analysts have also issued reports on the stock. Barclays lowered their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Stifel Nicolaus lifted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Raymond James lowered their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Royal Bank of Canada lowered their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, Truist Financial reiterated a “hold” rating and set a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Price Performance

ZBH stock opened at $103.98 on Monday. The firm has a 50 day moving average price of $105.63 and a 200-day moving average price of $107.28. Zimmer Biomet has a 52-week low of $97.69 and a 52-week high of $133.90. The firm has a market capitalization of $20.70 billion, a price-to-earnings ratio of 23.37, a PEG ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the business posted $2.20 EPS.

Hedge Funds Weigh In On Zimmer Biomet

Several hedge funds and other institutional investors have recently modified their holdings of ZBH. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Zimmer Biomet by 14.3% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 14,672 shares of the medical equipment provider’s stock valued at $1,584,000 after buying an additional 1,835 shares during the period. Pinnacle Associates Ltd. increased its stake in shares of Zimmer Biomet by 12.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,298 shares of the medical equipment provider’s stock worth $248,000 after purchasing an additional 252 shares in the last quarter. Financial Advocates Investment Management increased its stake in shares of Zimmer Biomet by 3.5% in the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after purchasing an additional 103 shares in the last quarter. Stephens Inc. AR purchased a new stake in shares of Zimmer Biomet in the 3rd quarter worth $638,000. Finally, Creative Financial Designs Inc. ADV increased its stake in shares of Zimmer Biomet by 23.6% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 771 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 147 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.